Voisin Consulting Life Sciences
Voisin Consulting Life Sciences is recorded as a service provider in 35 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 35 trials · Latest update first
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
The ADAPT Study: An Open-label, Long-term Safety Study of INZ-701 in Patients with ENPP1 Deficiency and ABCC6 Deficiency
Sponsor Inozyme Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Sponsor Inozyme Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations.
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis
Sponsor Leal Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3
Sponsor Biocodex
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
Sponsor Eip Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension
Sponsor Ablative Solutions Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis
Sponsor Zomagen Biosciences Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy
Sponsor Ovid Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy – The REVISE Study
Sponsor Gensight Biologics
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Sponsor Priovant Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
Sponsor Nuvalent Inc.
- Start (EU)
- Latest update
- Estimated end
A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants with Graves’ Disease (GD)
Sponsor Immunovant Sciences GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Voisin Consulting Life Sciences?
The 2026-10-09 snapshot links Voisin Consulting Life Sciences to 35 distinct CTIS trials. Recorded services include Regulatory services, Safety reporting & pharmacovigilance, Submissions, Data management, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Voisin Consulting Life Sciences?
The most frequently recorded therapeutic areas are Immunology, Cardiology, Genetic and Congenital Disorders, Neurology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Voisin Consulting Life Sciences conducted?
The linked trials record locations in 23 countries, including Germany, Spain, Italy, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Voisin Consulting Life Sciences delivered services.
What can this page tell me about Voisin Consulting Life Sciences's trial experience?
Browse 35 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Voisin Consulting Life Sciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Voisin Consulting Life Sciences